by LongeveronUS
Allogeneic MSC therapy from young donor bone marrow, tested in HLHS, Alzheimer's, frailty, and pediatric cardiomyopathy.
Missed its main goal in an infant heart defect (Sep 2026); company exploring strategic options.
Updated 25d agoChecked 11 Oct0 updates this week
MSCs are isolated from the bone marrow of young, healthy donors. These cells retain the regenerative and immunomodulatory properties that decline with age.
The therapy reduces inflammation, promotes new blood vessel formation, regenerates damaged tissue, and supports healing through multiple biological pathways.
Laromestrocel is delivered directly to affected tissues or infused systemically, depending on the indication.
| Spec | Laromestrocel (Lomecel-B) |
|---|---|
| Safety across programs | 644 patients treated, favorable safety maintainedR (reported) |
| ELPIS II trial size | 40 infants (20 treatment, 20 control)R (reported) |
| VITAL-H trial enrollment target | 726 adults ages 60-65R (reported) |
R reported by the company
Longeveron
Laromestrocel allogeneic MSC therapy, aging frailty, Alzheimer's
Longeveron develops laromestrocel, an allogeneic MSC therapy from young healthy donors. The company has FDA designations for HLHS and Alzheimer's disease. It is Nasdaq-listed and an XPRIZE Healthspan Milestone 2 awardee.
